Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study the global mRNA translation changes between SKBR cells overexpressing VIRMA and eGFP control

ABSTRACT: In order to determine whether increased m6A abundance coupled with upregulation of transcripts regulating UPR also promote their translation, we first compared levels of key UPR signalling proteins in VIRMA FL-overexpressing SKBR3 cells and eGFP control. To our surprise, none of the key UPR signalling proteins measured showed increased levels in VIRMA FL cells compared to control We then performed ribosome profiling analysis between SKBR cells overexpressing VIRMA FL and eGFP control

ORGANISM(S): Homo sapiens

PROVIDER: GSE205873 | GEO | 2023/08/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Effect of Overexpression of VIRMA on m6A-methylated mRNAs in breast cancer cells

Project description:To identify m6A-regulated mRNA targets affected by VIRMA overexpression we compared m6A peak abundance measured via m6A RNA immunoprecipitation sequenc-ing in SKBR3 cells overexpressing full-length VIRMA and eGFP control

2023-08-03 | GSE205892 | GEO

Human breast cancer SKBr-3 cells: trastuzumab-resistant vs. parental

2013-05-25 | GSE47011 | GEO

VIRMA-mediated m6A modification profilling in human nasopharyngeal carcinoma

Project description:Several studies revealed an underlying disordered m6A regulatory network in human nasopharyngeal carcinoma (NPC). However, the roles of m6A regulators and sequential m6A dysregulation in NPC remain largely unknown. In the present study, we investigated the role of VIRMA and its underlying mechanisms in NPC. We performed methylated RNA immunoprecipitation sequencing (MeRIP-seq) to identify the potential downstream targets of VIRMA that might be essential in NPC using HONE-1 cells with or without VIRMA silenced (two biological replicates).

2023-06-07 | GSE226363 | GEO

Effect of VIRMA amplification on gene expression in breast cancer cells

Project description:To confirm the contribution of elevated VIRMA levels towards cell proliferation and colony formation, we depleted VIRMA in four breast cancer cell lines, SKBR3, HS578T, MCF7 and MDAMB453 using short-hairpin RNAs (shRNAs). We then performed gene expression profiling analysis using data obtained from RNA-seq data

2023-08-03 | GSE205855 | GEO

KIAA1429/VIRMA promotes breast cancer proliferation and migration by stabilizing m6A-modified HAS2 RNA expression in cytosol

Project description:N6-methyladenosine (m6A) is the most abundant internal RNA modification in mRNA molecules and plays important roles in multiple important biological processes including cancer development. KIAA1429/VIRMA is an important component of m6A methyltransferase complex to facilitate depositing m6A modification in RNA molecules. Here we found that KIAA1429/VIRMA was overexpressed in breast cancer patients among other m6A related enzymes. Breast cancer patients with higher KIAA1429 expression have worse survival compared with control group. In addition, KIAA1429/VIRMA protein mislocated in cytosol in breast cancer tissues and cell lines. KIAA1429/VIRMA depletion reduced breast cancer cell proliferation and migration. Mechanism studies showed that cytosolic expressed KIAA1429/VIRMA interacted with m6A reader protein IGF2BP3 and stabilized expression of m6A-modified HAS2 expression. HAS2 is downstream of KIAA1429/VIRMA to mediate breast cancer cell proliferation and migration and has positive correlation with KIAA1429/VIRMA expression in cancer patients.

2021-11-02 | GSE185494 | GEO

Enhancer analysis of HER2+ cell lines SKBR-3 (ER-) and BT474m1 (ER+) in response to lapatinib and JQ1 and analysis of FOXA1 chromatin binding in SKBR-3 cells in response to lapatinib and JQ1 and impact of FOXA1 knockdown on BRD4 and MED1

Project description:SKBR-3 and BT474m1 HER2+ breast cancer cell lines were treated with lapatinib, JQ1, or lapatinib and JQ1 or (for SKBR-3) treated with siRNA pools (non-targeting control or FOXA1) prior to drug treatment before being used for ChIPseq (BRD4, MED1, H3K27Ac, or FOXA1 (for SKBR-3))

2020-11-03 | GSE160667 | GEO

Human breast cancer SKBr-3 cells: trastuzumab-resistant vs. parental

Project description:Human breast cancer SKBr-3 cells selected with trastuzumab for 6 month compared with parental SKBr-3 cells; Goal was to screen for microRNAs involved in development of trastuzumab resistance. Human breast cancer SKBr-3 cells were continuously cultured in the presence ofM-BM- 5M-BM-5g/ml trastuzumab for 6 months, and the resulting alive cells were regarded as trastuzumab-resistant. Total RNAs were prepared from these cells and cells cultured in parallel in control media, and were subjected to hybridization on the miRCURY LNA Array (Exiqon, version 11.0).

2013-05-25 | E-GEOD-47011 | biostudies-arrayexpress

VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation

Project description:N6-methyadenosine (m6A) is enriched in 3`UTR (3` untranslated region) and near stop codon of mature polyadenylated mRNAs in mammalian systems and has regulatory roles in eukaryotic mRNA transcriptome switch. Significantly, the mechanism for this modification preference remains unknown, however. Herein we report a characterization of the full m6A methyltransferase complex in HeLa cells identifying METTL3/METTL14/WTAP/VIRMA/HAKAI/ZC3H13 as the key components, and we show that VIRMA mediates preferential mRNA methylation in 3`UTR and near stop codon. Biochemical studies reveal that VIRMA recruits the catalytic core components METTL3/METTL14/WTAP to guide region-selective methylations. Around 60% of VIRMA mRNA immunoprecipitation targets manifest strong m6A enrichment in 3`UTR. Depletions of VIRMA and METTL3 induce 3`UTR lengthening of several hundred mRNAs with over 50% targets in common. VIRMA associates with polyadenylation cleavage factors CPSF5 and CPSF6 in an RNA-dependent manner. Depletion of CPSF5 leads to significant shortening of 3`UTR of over 2,800 mRNAs, 84% of which are modified with m6A. Together our studies provide insights into m6A deposition specificity in 3`UTR and its correlation with alternative polyadenylation.

2018-03-07 | GSE102493 | GEO

FOXA1-dependent responses of the HER2+ SKBR-3 cell line to lapatinib

Project description:SKBR-3 HER2+ breast cancer cells were treated with 25 nM Dharmacon siGENOME non-targeting (NT) siRNA control pool or siRNA pool targeting FOXA1 for 48h, then treated with either DMSO or 300nM lapatinib for 24h.

2020-10-26 | GSE160001 | GEO

Adaptive responses of the HER2+ SKBR-3 and BT474m1 cell lines to lapatinib and JQ1

Project description:SKBR-3 or BT474m1 HER2+ breast cancer cells were treated with either DMSO, 300nM lapatinib, 300nM JQ1, or lapatinib and JQ1 in combination for 48h.

2020-10-26 | GSE160018 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data